Multiple endocrine neoplasia type 1 associated with breast cancer: A case report and review of the literature

Jeong,Young  Ju; Oh,Hoon  Kyu; Bong,Jin  Gu

doi:10.3892/ol.2014.2144

Multiple endocrine neoplasia type 1 associated with breast cancer: A case report and review of the literature

Authors:
- Young Ju Jeong
- Hoon Kyu Oh
- Jin Gu Bong
View Affiliations

Affiliations: Department of Surgery, College of Medicine, Catholic University of Daegu, Nam‑gu, Daegu 705‑718, Republic of Korea, Department of Pathology, College of Medicine, Catholic University of Daegu, Nam‑gu, Daegu 705‑718, Republic of Korea
Published online on: May 13, 2014 https://doi.org/10.3892/ol.2014.2144
Pages: 230-234

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Multiple endocrine neoplasia type 1 (MEN1) is a cancer predisposition syndrome that includes a combination of endocrine and non‑endocrine tumors. The present study reports a rare case of MEN1 associated with breast cancer with the MEN1 gene mutation. A 45‑year‑old female was diagnosed with breast cancer subsequent to presenting with a right breast mass. Pre‑operative radiological studies indicated right breast cancer with a suspicious metastatic nodule of the lung. Further studies demonstrated bilateral thyroid nodules, a neuroendocrine tumor of the pancreas, paraganglioma, a left adrenal adenoma, gallstones, uterine subserosal myoma and pituitary macroadenoma. Laboratory examinations revealed hypercalcemia, hypophosphatemia and an increased intact parathyroid hormone level. The workup for the suspected MEN syndrome revealed an increased basal plasma level of insulin‑like growth factor‑1, prolactin and calcitonin, and an increased 24‑h urinary free cortisol level. The patient underwent surgical removal of the breast cancer and the tumors of the pancreas, adrenal gland, thyroid and parathyroid glands, uterus, anterior mediastinum and lung. The pathological diagnosis of the resected breast was of invasive ductal carcinoma. Otherwise the pathological diagnosis was of calcitonin‑producing pancreatic endocrine carcinoma, adrenal cortical adenoma, bilateral papillary thyroid carcinomas, parathyroid adenomas, uterine leiomyoma with adenomyosis, a thymic carcinoid tumor and lung hamatoma. Gene analysis was performed to determine the association between gene mutations and the development of tumors in this patient, and a germ‑line MEN1 gene mutation was consequently detected. It could be assumed that MEN1 syndrome may have possibly predisposed the present patient to breast cancer. However, additional observations and further studies are required to demonstrate this association.

View Figures

View References

1	Busygina V and Bale AE: Multiple endocrine neoplasia type 1 (MEN1) as a cancer predisposition syndrome: clues into the mechanisms of MEN1-related carcinogenesis. Yale J Biol Med. 79:105–114. 2006.
2	Chandrasekharappa SC, Guru SC, Manickam P, et al: Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science. 276:404–407. 1997.
3	Larsson C, Skogseid B, Oberg K, Nakamura Y and Nordenskjöld M: Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma. Nature. 332:85–87. 1988.
4	Thakker RV, Bouloux P, Wooding C, et al: Association of parathyroid tumors in multiple endocrine neoplasia type 1 with loss of alleles on chromosome 11. N Engl J Med. 321:218–224. 1989.
5	Farnebo F, Teh BT, Kytölä S, et al: Alterations of the MEN1 gene in sporadic parathyroid tumors. J Clin Endocrinol Metab. 83:2627–2630. 1998.
6	Brandi ML, Gagel RF, Angeli A, et al: Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab. 86:5658–5671. 2001.
7	Romei C, Pardi E, Cetani F and Elisei R: Genetic and clinical features of multiple endocrine neoplasia types 1 and 2. J Oncol. 2012:7050362012.
8	Morelli A, Falchetti A, Martineti V, et al: MEN1 gene mutation analysis in Italian patients with multiple endocrine neoplasia type 1. Eur J Endocrinol. 142:131–137. 2000.
9	Chung YJ, Kim HH, Kim HJ, et al: RET proto-oncogene mutations are restricted to codon 634 and 618 in Korean families with multiple endocrine neoplasia 2A. Thyroid. 14:813–818. 2004.
10	Kim BY, Lee DG, Lee KR, et al: Identification of BRCA1 and BRCA2 mutations from Korean breast cancer patients using denaturing HPLC. Biochem Biophys Res Commun. 349:604–610. 2006.
11	Giraud S, Zhang CX, Serova-Sinilnikova O, et al: Germ-line mutation analysis in patients with multiple endocrine neoplasia type 1 and related disorders. Am J Hum Genet. 63:455–467. 1998.
12	Honda M, Tsukada T, Horiuchi T, et al: Primary hyperparathyroidism associated with aldosterone-producing adrenocortical adenoma and breast cancer: Relation to MEN1 gene. Intern Med. 43:310–314. 2004.
13	Inic ZM, Inic M, Dodic R, Pupic G and Damjanovic S: Breast cancer in a patient with multiple endocrine neoplasia type 1 (MEN1): A case report and review of the literature. J Clin Oncol. 30(suppl): abstract 221136. 2012.
14	Papi L, Palli D, Masi L, et al: Germline mutations in MEN1 and BRCA1 genes in a woman with familial multiple endocrine neoplasia type 1 and inherited breast-ovarian cancer syndromes: a case report. Cancer Genet Cytogenet. 195:75–79. 2009.
15	Ghataorhe P, Kurian AW, Pickart A, et al: A carrier or both MEN1 and BRCA2 mutations: case report and review of the literature. Cancer Genet Cytogenet. 179:89–92. 2007.
16	Chandrasekharappa SC and Teh BT: Functional studies of the MEN1 gene. Functional studies of the MEN1 gene. J Intern Med. 253:606–615. 2003.
17	Knudson AG Jr: Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA. 68:820–823. 1971.
18	Lemos MC and Thakker RV: Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene. Hum Mutat. 29:22–32. 2008.
19	Kouvaraki MA, Lee JE, Shapiro SE, et al: Genotype-phenotype analysis in multiple endocrine neoplasia type 1. Arch Surg. 137:641–647. 2002.
20	Lips CJ, Dreijerink KM and Höppener JW: Variable clinical expression in patients with a germline MEN1 disease gene mutation: clues to a genotype-phenotype correlation. Clinics (Sao Paolo). 67(Suppl 1): 49–56. 2012.
21	Ellard S, Hattersley AT, Brewer CM and Vaidya B: Detection of an MEN1 gene mutation depends on clinical features and supports current referral criteria for diagnostic molecular genetic testing. Clin Endocrinol (Oxf). 62:169–175. 2005.
22	Klein RD, Salih S, Bessoni J and Bale AE: Clinical testing for multiple endocrine neoplasia type 1 in a DNA diagnostic laboratory. Genet Med. 7:131–138. 2005.
23	Park JH, Kim IJ, Kang HC, et al: Germline mutations of the MEN1 gene in Korean families with multiple endocrine neoplasia type 1 (MEN1) or MEN1-related disorders. Clin Genet. 64:48–53. 2003.
24	Agarwal SK, Guru SC, Heppner C, et al: Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription. Cell. 96:143–152. 1999.
25	Heppner C, Bilimoria KY, Agarwal SK, et al: The tumor suppressor protein menin interacts with NF-kappaB proteins and inhibits NF-kappaB-mediated transactivation. Oncogene. 20:4917–4925. 2001.
26	Kim H, Lee JE, Cho EJ, Liu JO and Youn HD: Menin, a tumor suppressor, represses JunD-mediated transcriptional activity by association with an mSin3A-histone deacetylase complex. Cancer Res. 63:6135–6139. 2003.
27	Itakura Y, Sakurai A, Katai M, et al: Enhanced sensitivity to alkylating agent in lymphocytes from patients with multiple endocrine neoplasia type 1. Biomed Pharmacother. 54(Suppl 1): 187s–190s. 2000.
28	Jin S, Mao H, Schnepp RW, et al: Menin associates with FANCD2, a protein involved in repair of DNA damage. Cancer Res. 63:4204–4010. 2003.
29	Binz SK, Sheehan AM and Wold MS: Replication protein A phosphorylation and the cellular response to DNA damage. DNA Repair (Amst). 3:1015–1024. 2004.
30	Kim YS, Burns AL, Goldsmith PK, et al: Stable overexpression of MEN1 suppresses tumorigenicity of RAS. Oncogene. 18:5936–5942. 1999.
31	Dreijerink KM, Mulder KW, Winkler GS, Höppener JW, Lips CJ and Timmers HT: Menin links estrogen receptor activation to histone H3K4 trimethylation. Cancer Res. 66:4929–4935. 2006.
32	Prest SJ, May FE and Westley BR: The estrogen-regulated protein, TFF1, stimulates migration of human breast cancer cells. FASEB J. 16:592–594. 2002.
33	Corte MD, Tamargo F, Alvarez A, et al: Cytosolic levels of TFF1/pS2 in breast cancer: Their relationship to clinical-pathological parameters and their prognostic significance. Breast Cancer Res Treat. 96:63–72. 2006.
34	Bauche E, Etique N, Alpy F, et al: Deficiency in trefoil factor 1 (TFF1) increases tumorigenicity of human breast cancer cells and mammary tumor development in TFF1-knockout mice. Oncogene. 30:3261–3273. 2011.
35	Amiry N, Kong X, Muniraj N, et al: Trefoil factor-1 (TFF1) enhances oncogenicity of mammary carcinoma cells. Endocrinology. 150:4473–4483. 2009.
36	Hähnel E, Robbins P and Hähnel R: Expression of the pS2 gene in normal breast tissue. Breast Cancer Res Treat. 28:295–297. 1993.
37	Poulsom R, Hanby AM, Lalani EN, Hauser F, Hoffmann W and Stamp GW: Intestinal trefoil factor (TFF 3) and pS2 (TFF 1), but not spasmolytic polypeptide (TFF 2) mRNAs are co-expressed in normal, hyperplastic, and neoplastic human breast epithelium. J Pathol. 183:30–38. 1997.